AstraZeneca Plc AZN on Tuesday reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4 ...
At ASCO 2026, AstraZeneca unveiled initial clinical data for AZD-3470 in relapsed/refractory classical Hodgkin lymphoma.
Investor's Business Daily on MSN
AstraZeneca scores in liver cancer on its path to $40 billion in oncology sales
AstraZeneca added to its Imfinzi armamentarium on Monday after the immuno-oncology drug led to improved survival in liver ...
The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...
This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical ...
(Reuters) - A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the rapidly-spreading Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from ...
People who receive AstraZeneca’s COVID-19 vaccine have a slightly increased risk of bleeding problems, according to a study published June 9 in Nature Medicine. Researchers observed adults in Scotland ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results